Want to join the conversation?
$PFE said Xeljanz has been prescribed to more than 50,000 patients worldwide. 2Q16 revenue was $217MM, representing 70% operational growth versus 2Q15. More than 3.5MM patients already have been prescribed Eliquis, and it is now the number one prescribed oral anticoagulant amongst cardiologists in the US, Japan and several European countries.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.
Well this is big! I don’t know if it’s someone’s monopoly or genuine excitement, but either way, $CSX is up 23% after market closed. I heard some activist investor is going to blow big money into CSX Corp. Anyone mind explaining?